SCHEMBL23218227

SCHEMBL23218227

CCOC(=O)Cc1ccccc1OCc1coc2c(CN3CCC(F)(F)CC3)cc(Br)cc12

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 6/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
TBXAS1 P24557 1/20 0.36
HTT P42858 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALOX15 P16050 1/20 0.34
GAA P10253 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218497 0.95 TBXAS1 (0.35) CCR5KMT2AMEN1TBXAS1HTT
SCHEMBL29852448 0.91 CCR5 (0.39) CCR5KMT2AMEN1TBXAS1HTT
SCHEMBL23218351 0.91 CCR5 (0.39) CCR5KMT2AMEN1TBXAS1HTT
SCHEMBL23219084 0.89 KDM4E (0.39) CCR5KMT2AMEN1TBXAS1HTT
SCHEMBL23218445 0.89 CCR5 (0.40) CCR5TBXAS1HTTL3MBTL1KDM4E
SCHEMBL28736146 0.88 KDM4E (0.39) CCR5KMT2AMEN1TBXAS1HTT
SCHEMBL29852449 0.86 CCR5 (0.40) CCR5KMT2AMEN1TBXAS1KDM4E
SCHEMBL23229202 0.86 CCR5 (0.40) CCR5KMT2AMEN1TBXAS1KDM4E
SCHEMBL23218822 0.86 TBXAS1 (0.40) KMT2AMEN1TBXAS1KDM4EALDH1A1
SCHEMBL29853078 0.86 TBXAS1 (0.40) KMT2AMEN1TBXAS1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CCR5 478/4885KMT2A 4445/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CCR5 1870/4885KMT2A 4835/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.